Royalty Pharma plc (RPRX) Thursday said it will host an Investor Day today, where senior executives will provide updates on the company's strategies aimed at driving shareholder value creation.
The company said it is on track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus. It expects to achieve at least mid-teens average annual total shareholder return over next 5 years.
The company is on track to meet or exceed its five-year capital deployment target of $10 billion to $12 billion as of January 1, 2022.
Since 2019, the company has achieved a 15% Return on Invested Capital (ROIC) and a 21% Return on Invested Equity (ROIE).
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.